Ikerian
Switzerland corporation · 22 employees on LinkedIn · 2 known investors
Ikerian applies data and AI to identify biomarkers linked to chronic and systemic disorders, aggregate clinical insights, and support treatment decisions. The company serves healthcare stakeholders and drug developers by curating information and optimizing clinical workflows and operations.
Also known as Ikerian AG · RetinAI
Founders & leadership
Investors · 2
.jpeg){kind=logo}
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 2 rounds · 2019–2024
▶$700KraisedDec 2025 · 5 investors · OtherRule 506(b)
- Carlos Ciller RuizExecutive Officer, Director
- Stefanos ApostolopoulosExecutive Officer, Director
- Sandro De ZanetExecutive Officer, Director
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Sep 2024
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
▶$7.9MraisedMar 2025 · 5 investors · OtherRule 506(b)
- Stefanos ApostolopoulosExecutive Officer, Director
- Sandro De ZanetExecutive Officer, Director
- Carlos Ciller RuizExecutive Officer, Director
- Offering amount
- $7.9M
- Amount sold
- $7.9M
- First sale
- May 2019
- Incorporated
- Corporation, Switzerland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Ikerian AG is a Swiss healthcare software company based in Bern that applies artificial intelligence to unstructured and multimodal medical data. Its platform, Discovery, is described as a modular healthcare software platform that organizes multimodal data at scale to produce structured insights for clinical and research use. Core capabilities include harmonizing multimodal data, extracting AI-based biomarker data, monitoring and predicting disease outcomes, identifying patients that match or do not match study criteria, and optimizing healthcare workflows.
The platform's biomarker library supports analysis across several therapeutic areas, including ophthalmology, neurology, cardiovascular disease, and rare diseases and 'omics'. Ikerian's first product, RetinAI, was focused on ophthalmology. The company states a mission of harmonizing and aggregating unstructured medical data at scale to create an open data ecosystem that improves understanding of patient disease and outcomes.
Business model
Ikerian provides a modular software platform (Discovery) to healthcare and life-sciences organizations, positioning itself as a vendor of data harmonization, AI biomarker extraction and workflow tooling rather than a care provider.
Traction
The company reports 15 pharmaceutical and research customers, more than 20 clinical studies processed, one million patient images, and more than 40 peer-reviewed research publications to date.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Ikerian positions itself as a provider of multimodal healthcare data infrastructure and AI biomarker analytics, with an initial foothold in ophthalmology via its RetinAI product that it has extended into neurology, cardiovascular, rare disease and 'omics' applications.
Ikerian emphasizes a modular platform combined with an extensive biomarker library that spans several therapeutic areas, and a team it describes as having more than ten years of work at the intersection of machine learning, imaging and healthcare decision workflows.
Technology
Ikerian's technology stack centers on machine learning applied to medical imaging and other multimodal clinical data. Stated core technologies include data harmonization across modalities, AI-based biomarker extraction, disease outcome monitoring and prediction, patient cohort screening against inclusion criteria, and healthcare workflow optimization. The company reports an extensive library of biomarkers spanning multiple therapeutic areas.
Go-to-market
Pharmaceutical companies, medical device manufacturers, clinics and hospitals, contract research organizations, and research institutions.
Geography
Headquartered at Freiburgstrasse 3, 3010 Bern, Switzerland, with an international team.
History
Company materials carry a copyright range beginning in 2016 for Ikerian AG. Its first product, RetinAI, addressed ophthalmology and preceded the broader Discovery platform covering additional therapeutic areas.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Legal entities · 1
corporate structure▸Research sources · 1
primary sources listed
- Ikerianikerian.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ikerian do?
- Swiss healthcare software company whose Discovery platform harmonizes multimodal medical data and extracts AI-based biomarkers.
- Who founded Ikerian?
- Ikerian was founded by Stefanos Apostolopoulos, Sandro De Zanet, Carlos Ciller Ruiz.
- Who are Ikerian's investors?
- Ikerian's investors include Matterwave Ventures, Verve Ventures.
- How much funding has Ikerian raised?
- Ikerian has disclosed $8.6M raised across 2 rounds.